Faecal Incontinence Clinical Trial
Official title:
Efficacy of Acupuncture as a Treatment for Faecal Incontinence
Overall Aim:
To improve the long-term management outcomes for faecal incontinence (FI); through the
implementation of new alternative treatment to complement existing treatment options, and
enable better utilization of limited healthcare resources.
Primary Specific Aim:
To evaluate the effectiveness of Traditional Chinese Medicine (TCM) acupuncture in the
treatment of faecal incontinence.
Secondary Aims:
- To evaluate the safety profile of TCM acupuncture.
- To explore the patient satisfaction and uptake of TCM acupuncture as an alternative
management strategy for FI.
- To evaluate improvements in health-related quality of life with TCM-acupuncture.
- To explore the cost-effectiveness of TCM acupuncture.
Hypothesis:
Traditional Chinese Medicine therapy, in the form of acupuncture, is an effective treatment
for faecal incontinence.
Experimental design and procedure The study will run as a prospective, multi-centre,
randomised controlled trial of patients with faecal incontinence of best medical therapy
versus TCM-Acupuncture.
Patient reported outcome measures and assessments will be carried out to assess primary and
secondary outcomes at the commencement of trial, after 10 weeks of the intervention, then
again at 15 weeks.
Recruitment procedure Patients will be recruited from Singapore General Hospitals' Colorectal
Surgery Department. SGH possess a fully staffed pelvic floor unit specialising in the
treatment of faecal incontinence. Eligible patients will be assessed and counselled by a
member of the colorectal surgical team. They will then attend for consenting and baseline
assessment.
The clinicians will inform the patient during the initial consultation about the different
treatments available for their condition as well as this study. As is normal clinical
practice, the clinicians will explain the risks and benefits of all the treatment options.
Each potential participant will be provided with a patient information sheet. Those who
consent to inclusion will then be contacted by a member of the research team. Informed
consent will be taken in the clinic environment.
Randomisation Patients will be randomised into one of two groups, to receive acupuncture
treatment (INTERVENTION GROUP) or to have best medical therapy (BMT) (CONTROL GROUP). Both
patients in the INTERVENTION GROUP and CONTROL GROUP will continue their previous medication,
if any, throughout the duration of the study. This is to standardise the 'steady-state'
existing in this often elderly population, already subject to polypharmacy.
Patients in the INTERVENTION GROUP will undergo acupuncture therapy at the Singapore College
of Traditional Chinese Medicine (SC-TCM), performed by a team of TCM practitioners regularly
using acupuncture in the treatment of faecal incontinence and bowel conditions. This regimen
will comprise 3 sessions per week each lasting 1 hour, over a period of 10 weeks, for a total
of 30 sessions.
Patients in the CONTROL GROUP will undergo BMT as defined previously for the same period of
10 weeks.
Patients will be asked to maintain a simple bowel diary, and answer the FIQL and St Marks'
incontinence scores at weeks 0, 10, and 15 to record the primary and secondary outcome
measurements. Anorectal Physiology will be offered to patients at 0 and 10 weeks, but for the
purposes of this study protocol, will be purely voluntary. We understand that this invasive
examination would be a significant undertaking and potential barrier to recruitment for many
patients.
Follow up procedure Patient follow-up will consist of three visits to the hospital following
the randomisation to either arm of the study. This will be at the 5 week period, 10 week
period and 15 week period of the study, where the primary and secondary outcomes measurements
will be assessed.
Randomisation and allocation Participants will be randomised to one of the two study groups
in equal proportion using a blinded bag shuffling method. This will take place upon agreement
to participate.
Measures of outcome Primary outcome: Bowel diary - Incontinence episodes per week Secondary
outcomes: St Marks' incontinence score, Faecal Incontinence Quality of Life (FIQL) score,
Anorectal manometry scores (at week 0, and 10 weeks) - optional for participants. Analysis
plans and sample size sought The primary end-point of the study was defined as the difference
in weekly faecal incontinence episodes when comparing patients randomized to the INTERVENTION
and CONTROL arms. The secondary endpoint of the study was defined as the difference in St
Marks' score and FIQL when comparing patients randomized to the INTERVENTION and CONTROL
arms.
Sample Size To detect a difference of 30% between the two arms, assuming that the proportion
of incontinence episodes in the conservative arm is 20%, a total sample size of 90 will be
required at alpha=0.05 with 80% power. Accounting for a drop-out rate of 10%, the total
sample size required is 100, to be recruited over 30 months.
Statistical analysis Continuous data will be summarized as mean (SD) or median (IQR) as
appropriate and categorical/binary data as frequency (%). Statistical significance will be
set at 0.05. Intention to treat (ITT) analysis will be performed.
The primary hypothesis will be evaluated using a Chi-square test or a Fisher's exact test as
appropriate. Additionally, we will also model the outcome using a generalized linear model
with a logit link. The possible treatment effect modification of clinically important factors
(age, gender, ASA status) will be evaluated in the model.
The secondary hypothesis to evaluate the St Marks' score will be assessed using a two-sample
t-test assuming that the score can be treated as a continuous measure. The difference in the
FIQL between the two arms will also be tested using the two-sample t-test.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|
||
Completed |
NCT02292628 -
Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence
|
Phase 1/Phase 2 | |
Recruiting |
NCT04612569 -
Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
|
||
Completed |
NCT05049486 -
Computational Model of SNS (Sacral Nerve Stimulation) Induced Electrical Current Flow Using Tractography Imaging
|
N/A | |
Completed |
NCT02782364 -
Evaluation of the Fast Fill Technique for Anal Acoustic Reflectometry (AAR) in the Incontinent Anal Sphincter
|
||
Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
Completed |
NCT03261622 -
Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective
|
N/A | |
Recruiting |
NCT03969069 -
Assessment of Faecal Incontinence With MAPLe
|
||
Recruiting |
NCT05245565 -
Effects of Modified Precision Functional Sphincter-Preserving Surgery (PPS) on Ultralow Rectal Cancer
|
||
Completed |
NCT03078634 -
The Multi-disciplinary Treatment of Functional Gut Disorders Study
|
N/A | |
Recruiting |
NCT05900726 -
Pelvipower for Faecal Incontinence
|
N/A | |
Recruiting |
NCT05550675 -
Prospective Database of Factors Associated With Faecal vs. Double Incontinence in Patients Referred for High Resolution Anorectal Manometry.
|
||
Recruiting |
NCT04657588 -
Controlling Faecal Incontinence With a Novel Anal Device: a Cost-effectiveness Trial
|
N/A | |
Active, not recruiting |
NCT04262609 -
Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy
|
||
Completed |
NCT05016453 -
Long-term Efficacy of Percutaneous Tibial Nerve Stimulation Applied to Patients With Faecal Incontinence.
|
||
Completed |
NCT04007250 -
FENIX™ Continence Restoration System Registry
|
||
Completed |
NCT02349334 -
UK Trial of Percutaneous Tibial Nerve Stimulation in Patients With Faecal Incontinence
|
Phase 3 | |
Recruiting |
NCT06143072 -
CArE for OAsI Study: Care Pathways and Anorectal Evaluation for OASI Associated Incontinence
|
||
Completed |
NCT01656720 -
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period
|
Phase 2 | |
Withdrawn |
NCT00420797 -
A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence
|
Phase 3 |